Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Blood (2025) 146 (Supplement 1): 2715.

https://doi.org/10.1182/blood-2025-2715

Published: 2025

Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

Blood (2025) 146 (Supplement 1): 906.

https://doi.org/10.1182/blood-2025-906

Published: 2025

Journal Articles

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Jessica Leonard, Abdullah Ladha, Rawan Faramand, Gregory Roloff, Yannis Valtis, Virginia Tan, Katharine Miller, Amy Zhang, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Sumithira Vasu, Evandro Bezerra, Kristen O'Dwyer, Jozal Moore, Eunice Wang, Ross McCauley, Navneet Majhail, Aravind Ramakrishnan, Luke Mountjoy, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Hrishikesh Srinagesh, Katherine Sutherland, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Caspian Oliai, Georgia Lill, Wendy Stock, Marc Schwartz, Tamer Othman, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, Punita Grover, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Noelle Frey, Lori Muffly, Bijal Shah, Ibrahim Aldoss

Blood (2025) 146 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2025-3365

Published: 2025

Journal Articles

Real-world treatment patterns, outcomes, and unmet needs in patients with ph+ ALL receiving tyrosine kinase inhibitors in the United States: Emerging trends and the role of asciminib-based combinations

Marlise Luskin, Andrea Damon, Emily McGovern, Dominick Latremouille-Viau, Annie Guerin, Carmine Rossi, Fredrick Kinkhead, Gabriel Marquez, David Wei, Islam Mohamad Sadek, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5097.

https://doi.org/10.1182/blood-2025-5097

Published: 2025

Journal Articles

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Ross McCauley, Amy Zhang, Vamsi Kota, Jacob Boccucci, Michael Grunwald, Matthew Ulrickson, LaQuisa Hill, Ibrahim Muhsen, Joshua Sasine, Anjali Advani, Ibrahim Aldoss, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Silvina Odstrcil Bobillo, Stephanie Tsai, Talal Hilal, Bijal Shah, Rawan Faramand, Jae Park, Yannis Valtis, Tamer Othman, Sumithira Vasu, Evandro Bezerra, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Aaron Logan, Michael Daunov, Ken Byrd, Fevzi Yalniz, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Ali Al-Darobi, Evan Chen, Catherine Lee, Timothy O'Connor, Bhagirathbhai Dholaria, Veronika Bachanova, Sean Tracy, Hrishikesh Srinagesh, Katharine Miller, Katherine Sutherland, Navneet Majhail, Luke Mountjoy, Shahbaz Malik, Aravind Ramakrishnan, Paul Shaughnessy, John Mathews, Eunice Wang, Minoo Battiwalla, Gregory Roloff, Lori Muffly

Blood (2025) 146 (Supplement 1): 2396.

https://doi.org/10.1182/blood-2025-2396

Published: 2025

Journal Articles

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Archana Sasi, Victor Kovac, Yiwen Liu, Jessica Little, Ann Woolley, Harrison Tsai, Vincent Ho, Shai Shimony, Eric Winer, Richard Stone, Daniel Deangelo, Marlise Luskin, Lindsey Baden, R. Coleman Lindsley, Rahul Vedula

Blood (2025) 146 (Supplement 1): 5180.

https://doi.org/10.1182/blood-2025-5180

Published: 2025

Journal Articles

Early TCR diversity and recipient stem-cell persistence predict relapse and reveal therapeutic targets after allogeneic transplantation

Blood (2025) 146 (Supplement 1): 6065.

https://doi.org/10.1182/blood-2025-6065

Published: 2025

Journal Articles

Molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL

Stella Jaeckle, Emma Smith, Jeremy Ryan, Chase Weizer, Matthew Booker, Ashreen Williams, Michael Tolstorukov, Daniel Deangelo, Marlise Luskin, Anthony Letai, Mark Murakami

Blood (2025) 146 (Supplement 1): 329.

https://doi.org/10.1182/blood-2025-329

Published: 2025

Journal Articles

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

Andrew Lane, Marlise Luskin, Julia Keating, Nicole Leboeuf, Jacqueline Garcia, Shai Shimony, Rebecca Leonard, Adon Goodpaster, Theresa Nguyen, Ilene Galinsky, Ashleigh Eberly-Puleo, Naval Daver, Nitin Jain, Guillermo Garcia-Manero, Hagop Kantarjian, Marina Konopleva, Anthony Selwyn Stein, Naveen Pemmaraju

Blood (2025) 146 (Supplement 1): 653.

https://doi.org/10.1182/blood-2025-653

Published: 2025

Journal Articles

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial

Marlise Luskin, Julia Keating, Benjamin Frost, Yael Flamand, Jacqueline Garcia, Richard Stone, Rebecca Leonard, Stella Jaeckle, Chase Weizer, Jessica Lee, Ilene Galinsky, Jeremy Ryan, Eric Winer, Evan Chen, Anthony Letai, Mark Murakami, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 645.

https://doi.org/10.1182/blood-2025-645

Published: 2025

Journal Articles

Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization

Yannis Valtis, Benjamin Frost, David Nemirovsky, Andriy Derkach, Kuo-Kai Chin, Meira Yisraeli Salman, Leora Boussi, Natalia Tijaro Ovalle, Eytan Stein, Emilie Baxter, Mark Geyer, Marlise Luskin, Daniel Deangelo, Jae Park, Evan Chen

Blood (2025) 146 (Supplement 1): 1078.

https://doi.org/10.1182/blood-2025-1078

Published: 2025

Journal Articles

Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes

Katherine Feder, Jessica Freydman, Yue Ren, Shruti Gajjar, Victor You, David Sirignano, Svitlana Tyekucheva, Andrew Brunner, Jean M. Connors, Daniel Deangelo, Amir Fathi, Jacqueline Garcia, Chi-Joan How, Marlise Luskin, Richard Stone, Virginia Volpe, Michelle Lee, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 7338.

https://doi.org/10.1182/blood-2025-7338

Published: 2025

Journal Articles

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Aaron Logan, Fevzi Yalniz, Amy Zhang, Katharine Miller, Katherine Sutherland, Nikeshan Jeyakumar, Hrishikesh Srinagesh, Michael Grunwald, Vamsi Kota, Jacob Boccucci, Matthew Ulrickson, Ali Al-Darobi, Joshua Sasine, LaQuisa Hill, Ibrahim Muhsen, Anjali Advani, Ibrahim Aldoss, Tamer Othman, Karamjeet Sandhu, Ran Reshef, Marlise Luskin, Evan Chen, Chenyu Lin, Ryan Cassaday, Noam Kopmar, Melhem Solh, Catherine Lee, Silvina Odstrcil Bobillo, Stephanie Tsai, Timothy O'Connor, Talal Hilal, Jae Park, Yannis Valtis, Sumithira Vasu, Evandro Bezerra, Eunice Wang, Jessica Leonard, Virginia Tan, Kristen O'Dwyer, Jozal Moore, Ross McCauley, Navneet Majhail, Luke Mountjoy, Aravind Ramakrishnan, Shahbaz Malik, Minoo Battiwalla, Paul Shaughnessy, John Mathews, Omer Jamy, Razan Mohty, Muthu Kumaran, Rasmus Hoeg, Wendy Stock, Gregory Roloff, Caspian Oliai, Georgia Lill, Marc Schwartz, Divya Koura, Kaitlyn Dykes, Michael Daunov, Ken Byrd, Veronika Bachanova, Sean Tracy, Punita Grover, Noelle Frey, Matthew Connor, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan Oluwole, Bhagirathbhai Dholaria, Rawan Faramand, Lori Muffly

Blood (2025) 146 (Supplement 1): 516.

https://doi.org/10.1182/blood-2025-516

Published: 2025

Journal Articles

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Blood (2025) 146 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2025-3329

Published: 2025

Journal Articles

Prevalence and significance of cytoses in clonal hematpoiesis

Virginia Volpe, Keishla Arce-Ruiz, Yating Wang, Caitlyn Vlasschaert, Md Mesbah Uddin, Pradeep Natarajan, Daniel Deangelo, Alexander Bick, Marlise Luskin, R. Coleman Lindsley, Shai Shimony, Lachelle Weeks

Blood (2025) 146 (Supplement 1): 1387.

https://doi.org/10.1182/blood-2025-1387

Published: 2025

Journal Articles

A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis

Riya Nandi, Caitlyn Vlasschaert, Md Mesbah Uddin, Pradeep Natarajan, Daniel Deangelo, Marlise Luskin, R. Coleman Lindsley, Alexander Bick, Shai Shimony, Lachelle Weeks

Blood (2025) 146 (Supplement 1): 1386.

https://doi.org/10.1182/blood-2025-1386

Published: 2025

Journal Articles

Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia

Rahul Vedula, Hannah Karp, Danielle Morrow, Andrew Gehrke, Yiwen Liu, Ellen Weisberg, Carter Lombardi, Rebecca Leonard, Ilene Galinsky, Jacqueline Garcia, Marlise Luskin, Maximilian Stahl, Martha Wadleigh, Eric Winer, Daniel Deangelo, James Griffin, Richard Stone, R. Coleman Lindsley

Blood (2025) 146 (Supplement 1): 3265.

https://doi.org/10.1182/blood-2025-3265

Published: 2025

Journal Articles

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Blood (2019) 134 (Supplement_1): 2015.

https://doi.org/10.1182/blood-2019-126238

Published: 2019

Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS

Blood (2019) 134 (Supplement_1): 3908.

https://doi.org/10.1182/blood-2019-124966

Published: 2019

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults

Marlise Luskin, MDMS, Mark A. Murakami, MDMA,MMSc, Kristen E. Stevenson, MS, Martha Wadleigh, MD, Malgorzata McMasters, MD, Peter Winter, PhD, David M. Weinstock, MD, Richard Stone, MD, Daniel J. DeAngelo, MD PhD

Blood (2019) 134 (Supplement_1): 3879.

https://doi.org/10.1182/blood-2019-125138

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)

Real-world treatment patterns, outcomes, and unmet needs in patients with ph+ ALL receiving tyrosine kinase inhibitors in the United States: Emerging trends and the role of asciminib-based combinations

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Early TCR diversity and recipient stem-cell persistence predict relapse and reveal therapeutic targets after allogeneic transplantation

Molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial

Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization

Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Prevalence and significance of cytoses in clonal hematpoiesis

A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis

Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia

Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only